Yu-Chien Chou

Dr. Chou has over 15 years of hands-on research experience in preclinical pharmacology, translational oncology and biomarker strategies for therapeutic drug discovery. Prior to joining Ensigna Biosystems, she led teams at Exelixis responsible for in vivo characterization of developmental compounds for numerous oncology and metabolic disease programs. She also worked as an oncology scientist in Experimental Pathology/Translational Sciences at Novartis. She has held positions at the Lawrence Berkeley National Laboratory and UC Berkeley, making significant contributions to the understanding of mammary carcinogenesis. Her sphere of expertise includes PK/PD/efficacy, tissue-based biomarker analysis supporting lead optimization, translational research and IND filings, immunohistochemistry and antibody validation. Dr. Chou received her Ph.D. (Endocrinology and Cancer Biology) from UC Berkeley and a B.S. degree (Biology) from Yokohama City University, Japan. In her role as Vice President, Dr. Chou is managing the histopathology facility and building the histology team, using automated immunohistochemistry technologies to aid in antibody validation and biomarker strategy.